Development of Lower-Cost, More Compact geneLEAD VIII and Multiple Diagnostic Reagents
First written in FY2016. 5 of 13 entries say "Advanced", first in FY2017-Q3. Latest entry: FY2025.
Precision System Science moved to the "Worse" side of this theme in 2025.
1 other company's latest entry also says "Reframed".
- FY2025ReframedAnnual report
「The latest priority themes for product commercialization using our proprietary technologies are as follows.」
The presentation shifted from descriptions centered on new product development for geneLEAD VIII and XXIV to a structure identifying GlycoBIST, LuBEA, new PCR parameters, and nucleic-acid extraction applications as priority themes. - FY2024-Q1RestatedAnnual report
「Under these circumstances, as a biotechnology venture, our group is pursuing new product development based on the market-launch roadmap, considering new testing businesses, and reforming our business operations.」
The development policy based on the roadmap for launching new products, including geneLEAD XXIV, remained in place. - FY2023RestatedAnnual report
「We plan to launch new products including the pressure-ulcer prevention mat Sasakaze, the new magLEAD12gCLINK, and geneLEADXXⅣ.」
Plans to launch new products, including geneLEAD XXIV, remained in place. There was no statement that the market launch had been completed. - FY2020AdvancedAnnual report
「Recent product application development includes products for biobanks and the development and market launch of series products such as geneLEAD XXIV (24), which has high-throughput specimen processing capacity. These products are intended to establish PCR testing capacity to protect lives and the economy from the threat of serious infectious diseases, including COVID-19.」
Newly added were development for biobank applications, COVID-19-related development, and targets for developing and launching products such as geneLEAD XXIV, which has high-throughput specimen processing capacity, as applications following the commercialization of geneLEAD VIII. - FY2019RestatedAnnual report
「We have commercialized geneLEAD Ⅷ, an inexpensive, compact, fully automated genetic testing system and a new in-house branded model, and are conducting application development under the geneLEAD series to meet a wide range of customer needs. We are also developing genetic extraction reagents and test reagents compatible with multiple specimen types and diagnostic parameters for use with these systems.」
geneLEAD Ⅷ had been commercialized, while application development for the geneLEAD series and reagent development for multiple specimen types and diagnostic parameters were continuing. - FY2019-Q3RestatedAnnual report
「The Company has determined that no material uncertainty exists regarding the going-concern assumption because the new fully automated genetic testing system, geneLEAD Ⅷ, and testing reagents have been launched.」
The status of geneLEAD Ⅷ and the test reagents as already launched was reconfirmed. - FY2019-Q2RestatedAnnual report
「The Company has determined that no material uncertainty exists regarding the going-concern assumption because the new fully automated genetic testing system, geneLEAD Ⅷ, and testing reagents have been launched.」
The status of geneLEAD Ⅷ and the test reagents as already launched was reconfirmed. - FY2019-Q1AchievedAnnual report
「The Company has determined that no material uncertainty exists regarding the going-concern assumption because the new fully automated genetic testing system, geneLEAD Ⅷ, and testing reagents have been launched.」
The description of geneLEAD Ⅷ and the test reagents progressed from the previous stage of expected development and market launch to a statement that they had been launched. - FY2018AdvancedAnnual report
「Research and development expenses were ¥568 million, down 12.2% year on year, mainly reflecting development costs for geneLEAD Ⅷ, which is in the final stage before commercialization. The Company also worked to reduce other expenses, bringing selling, general and administrative expenses to ¥1,697 million, down 5.0%.」
The Company reported that geneLEAD Ⅷ had progressed from ongoing development to the final stage before commercialization. It did not state that the launch had been completed. - FY2018-Q3AdvancedAnnual report
「The Company has determined that no material uncertainty exists regarding the going-concern assumption, as sales of the fully automated genetic diagnostic system supplied as an OEM product to ELITechGroup and own-brand sales have performed well, and the launch of the new fully automated genetic diagnostic system, geneLEAD Ⅷ, and diagnostic reagents is expected.」
The Company reported new progress toward commercialization of geneLEAD Ⅷ and the diagnostic reagents, describing them as expected to be launched rather than merely under continued development. It did not state that the launch had been completed. - FY2017AdvancedAnnual report
「As a measure to expand future earnings, the Company is developing a low-cost, compact fully automated genetic diagnostic system, geneLEAD Ⅷ, a significant advancement of the currently marketed geneLEAD Ⅻ plus incorporating its accumulated technologies and cost-reduction approach, together with genetic extraction reagents and diagnostic reagents compatible with multiple specimen types and diagnostic targets.」
geneLEAD Ⅷ and the reagents and diagnostic reagents compatible with multiple specimen types and diagnostic targets were specifically described as development projects approaching the final stage before commercialization. - FY2017-Q3AdvancedAnnual report
「② Hitachi High-Tech will sell the compact genetic testing system and its reagents developed by the Company. ③ Using the technologies of the Company and Hitachi High-Tech, Hitachi High-Tech will develop and sell a medium-sized genetic testing system. The reagents will be developed by the Company and third parties and sold by Hitachi High-Tech.」
The cooperation framework under which Hitachi High-Tech will serve as the sales channel for the compact genetic testing system has taken concrete shape. The scope has also expanded to include the development and sale of a medium-sized genetic testing system. - FY2016First statedAnnual report
「The Company is developing a low-cost, compact fully automated genetic diagnostic system, geneLEAD Ⅷ, a significant advancement of the currently marketed geneLEAD Ⅻ plus and a new own-brand model, as well as multiple genetic diagnostic reagents to be used with it.」
The Company is simultaneously pursuing the development of a lower-cost, more compact version of its existing model and multiple diagnostic reagents for use with its own-brand model.